Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
    Michalski, J. M.
    Golden, G.
    Ikari, J.
    Rennard, S. I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (01) : 134 - 142
  • [2] Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors
    Halpin, David M. G.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2006, 67 (07) : 370 - 374
  • [3] Discovery of novel and orally active quinolyl oxazole-based PDE4 inhibitors for the treatment of chronic obstructive pulmonary disease and asthma
    Kuang, Rongze
    Shue, Ho-Jane
    Blythin, David
    Ting, Pauline
    Shih, Neng-Yang
    Xiao, Li
    Chen, Xiao
    Gu, Danlin
    Schwerdt, John
    Cao, Jianhua
    Wu, Heping
    Prelusky, Dan
    Sorota, Steve
    Wu, Ping
    Zhang, Ji
    Zhang, Xiang
    Celly, Chander
    Billah, Motasim
    Wang, Peng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [4] Ensifentrine (RPL554): an inhaled "bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease
    Cazzola, Mario
    Page, Clive
    Calzetta, Luigino
    Matera, Maria Gabriella
    PHARMACEUTICAL PATENT ANALYST, 2018, 7 (06) : 249 - 257
  • [5] Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease
    Dunne, Amy E.
    Kawamatawong, Theerasuk
    Fenwick, Peter S.
    Davies, Ceri M.
    Tullett, Hannah
    Barnes, Peter J.
    Donnelly, Louise E.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2019, 60 (04) : 445 - 453
  • [6] The inhaled PDE4 inhibitor tanimilast shows efficacy in both Th2 and non-Th2 murine models of asthma
    Pisano, Rita
    Fragni, Debora
    Allen, Andrew
    Tondelli, Marina
    Pappani, Alice
    De Angelis, Davide
    Civelli, Maurizio
    Villetti, Gino
    Miglietta, Daniela
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [7] Effects of the Novel Inhaled Phosphodiesterase-4 (PDE4) Inhibitor CHF6001 in Targeting Markers of Inflammation in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis
    Singh, D.
    Govoni, M.
    Beeh, K. M.
    Colgan, B.
    Kornmann, O.
    Leaker, B.
    Watz, H.
    Lucci, G.
    Geraci, S.
    Rocco, E. Calabro
    Emirova, A.
    Nandeuil, M. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [8] Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease
    Liang, Yingmin
    Mak, Judith C. W.
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (12) : 1469 - 1481
  • [9] The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils
    Schioppa, Tiziana
    Nguyen, Hoang Oanh
    Salvi, Valentina
    Maugeri, Norma
    Facchinetti, Fabrizio
    Villetti, Gino
    Civelli, Maurizio
    Gaudenzi, Carolina
    Passari, Mauro
    Sozio, Francesca
    Barbazza, Ilaria
    Tamassia, Nicola
    Cassatella, Marco A.
    Del Prete, Annalisa
    Bosisio, Daniela
    Tiberio, Laura
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
  • [10] Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective
    Gan, Qiming
    Wu, Yanjuan
    Su, Xiaofen
    Wang, Jingcun
    Zhang, Haojie
    Zhang, Nuofu
    Wu, Kang
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (02) : 223 - 224